Mechanistic and Molecular Study of the Process of Metastatic Dissemination in Colorectal Cancer

Overview

To confirm the role of the collective dissemination in the mechanisms of tumoral invasion of colorectal cancers

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2020

Interventions

  • Procedure: Sampling
    • After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples. The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern: Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal Peritoneal liquid none tumoral peritoneum Portal blood Peripheral blood Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum. In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator.

Arms, Groups and Cohorts

  • Other: Patients with metastatic colorectal cancer
    • After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples. The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern: Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal Peritoneal liquid none tumoral peritoneum Portal blood Peripheral blood Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum. In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator.

Clinical Trial Outcome Measures

Primary Measures

  • Identification and characterization of the tumoral intermediaries on the overflowing peritoneal
    • Time Frame: Up to 24 months
    • After several separation and centrifugation steps, clusters and tumor cells are isolated and counted in the various biological samples. The different isolated intermediates will be analyzed by immunolabeling with the antibodies directed against CK20, EpCAM, Vimentine and CD45.
  • Identification and characterization of the tumoral intermediaries on the portal blood
    • Time Frame: Up to 24 months
    • After several separation and centrifugation steps, clusters and tumor cells are isolated and counted in the various biological samples. The different isolated intermediates will be analyzed by immunolabeling with the antibodies directed against CK20, EpCAM, Vimentine and CD45.
  • Identification and characterization of the tumoral intermediaries on the peripheral blood
    • Time Frame: Up to 24 months
    • After several separation and centrifugation steps, clusters and tumor cells are isolated and counted in the various biological samples. The different isolated intermediates will be analyzed by immunolabeling with the antibodies directed against CK20, EpCAM, Vimentine and CD45.
  • Identification and characterization of the tumoral intermediaries on the hepatic metastasis and/or peritoneal)
    • Time Frame: Up to 24 months
    • After several separation and centrifugation steps, clusters and tumor cells are isolated and counted in the various biological samples. The different isolated intermediates will be analyzed by immunolabeling with the antibodies directed against CK20, EpCAM, Vimentine and CD45.

Participating in This Clinical Trial

Inclusion Criteria

  • Age > 18 years
  • Histological Diagnosis of stage IV colorectal cancer
  • Hepatic metastasis and/or peritoneal potentially resecable
  • Patient affiliated with a mode of the social security or recipient of such a mode
  • Information of the patient or his legal representative and collection of his assent

Exclusion Criteria

  • None metastatic colorectal cancer
  • Cancer of appendicular origin
  • Patients deprived of liberty or unable to give his assent

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Gustave Roussy, Cancer Campus, Grand Paris
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Diane GOERE, MD, 0142114211, diane.goere@gustaveroussy.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.